成骨不全症治療市場：依藥物、給藥途徑及地區分類

Osteogenesis Imperfecta Treatment Market, By Drugs By Route of Administration, and By Region

出版日期: 2026年04月27日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，成骨不全症治療市場規模將達到 7.779 億美元，到 2033 年將達到 9.31 億美元。預計 2026 年至 2033 年的複合年成長率為 2.6%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	7.779億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	2.60	2033年市場規模預測：	9.31億美元

成骨不全症（OI）是一種影響骨骼的遺傳性疾病，會阻礙身體形成強壯的骨骼。這種疾病會導致骨骼脆弱易碎，且骨折原因不明。成骨不全症也被稱為“骨形成不全”，患者的骨骼容易發生骨折或斷裂。因此，這種疾病通常被稱為「脆性骨營養不良」。在嚴重的成骨不全症病例中，患者經常發生多處骨折，而在輕度病例中，患者一生中可能只發生幾次骨折。患有這種疾病的人天生就無法產生結締組織，或者其基因異常阻礙了結締組織的形成。這會影響膠原蛋白的合成，而膠原蛋白是一種能夠強化骨骼的結締組織蛋白。成骨不全症分為兩種：I型和IX型，其中I型病情較輕，而IX型則可能致命。成骨不全症的主要徵兆是頻繁骨折。其他症狀包括關節鬆弛、骨骼畸形、聽力喪失、呼吸系統問題和牙齒問題。成骨不全症的診斷主要依賴DNA檢測和膠原蛋白檢測。由於它是一種遺傳性疾病，目前尚無根治性。健康的生活方式有助於預防骨折，例如運動和戒菸。穿戴矯正器具、服用止痛藥、妥善的骨折照護也十分有效。抗生素和消毒劑可用於治療骨骼感染疾病。預計在預測期內，全球成骨不全症治療市場將因對新型療法的需求不斷成長，以及主要行業參與者為開發成骨不全症治療方法而達成的許可協議和戰略合作，而推動全球成骨不全症治療市場的成長。

市場動態

研發資金的激增，尤其是用於開發新型治療方法的資金投入，是推動全球成骨不全症治療市場成長的主要動力。此外，主要產業參與者在成骨不全症治療藥物開發方面的許可和策略合作也是推動市場成長的另一個因素。成骨不全症是一種遺傳性疾病，由於成骨不全症患者的家族病史，全球病例數量不斷增加，預計將進一步推動市場成長。例如，2021年5月，Mereo BioPharma Group plc發表了一項針對IV型、III型或I型成骨不全症成年患者的II-B期臨床試驗的6個月數據，結果令人鼓舞。本試驗採用cetrumab（BPS-804）進行治療。歐洲藥品管理局（EMA）已批准該公司針對BPS-804的兒童臨床試驗計劃和註冊研究設計，該候選藥物目前已準備好開展針對兒童患者的III期臨床試驗。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並說明了該市場極具吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球成骨不全症治療市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球成骨不全症治療市場報告針對該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析全球成骨不全症治療市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

BioSenic SA
Mereo Biopharma Group PLC
CELGENE CORPORATION
Eli Lilly and Company
Cipla Inc.
Amgen Inc.
Sun Pharmaceutical Industries Ltd.
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Jubilant Pharmova Limited
Aurobindo Pharma
Quince
Ultragenyx Pharmaceutical Inc.
OrthoPediatrics Corp.

第8章

調查方法
關於本公司

簡介目錄

Product Code: CMI4064

Osteogenesis Imperfecta Treatment Market is estimated to be valued at USD 777.9 Mn in 2026 and is expected to reach USD 931.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 2.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 777.9 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	2.60%	2033 Value Projection:	USD 931.0 Mn

Osteogenesis imperfect, or OI, is a genetic disorder that affects the bones and also prevents the body from building strong bones. This disease makes the bones brittle and breaks easily without any cause. OI is referred to as imperfect bone formation, and people suffering from this disorder have bones that fracture or break easily. Therefore, this condition is also commonly known as brittle bone disease. In severe OI cases, multiple fractures are common, whereas a milder case involves a few fractures or bone breaks in a person's lifetime. People with this condition are either born unable to produce connective tissue or have it due to faulty genes. It has an impact on the synthesis of collagen, the connective tissue protein that strengthens bones. The illness comes in I and IX forms, with I being mild and IX being fatal. The major sign of osteogenesis imperfecta is frequent fractures. Other symptoms include loose joints, deformed bones, loss of hearing, breathing issues, and tooth problems. Osteogenesis imperfecta can be confirmed through DNA or collagen testing. There is no treatment for it because it is a genetic condition. Exercise and giving up smoking are two examples of healthy lifestyle choices that can help prevent fractures. Braces, painkillers, and correct bone fracture care are all beneficial. Antibiotics and antiseptics can be used to treat bone infections. Rising demand for novel therapies for osteogenesis imperfecta treatment and licensing agreements and strategic collaborations by key industry players for the development of OI treatment are expected to propel the growth of global osteogenesis imperfecta treatment market over the forecast period.

Market Dynamics

The surge in funding for research & development to develop novel treatment and therapies is a major factor boosting growth of the global osteogenesis imperfecta treatment market. Moreover, licensing agreements and strategic collaborations by key industry players for the development of OI treatment is another factor propelling the market growth. Moreover, osteogenesis imperfecta is a genetic disorder and the family history of people with OI is resulting in rising number of cases across the globe, which is expected to drive the market growth. For instance, in May 2021, Mereo BioPharma Group plc announced encouraging 6-month data from its phase II-B clinical study in adult patients with Type IV, III, or I osteogenesis imperfecta treated with setursumab (BPS-804). The European Medicines Agency (EMA) had approved the company's pediatric investigation plan for BPS-804 and with a registration study design, and the drug candidate is now phase III ready for a pediatric population.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global osteogenesis imperfecta treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are BioSenic SA, Mereo Biopharma Group PLC, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Jubilant Pharmova Limited, Aurobindo Pharma, Quince, Ultragenyx Pharmaceutical Inc. and OrthoPediatrics Corp.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global osteogenesis imperfecta treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteogenesis imperfecta treatment market

Detailed Segmentation:

Global Osteogenesis Imperfecta Treatment Market, By Drugs (Revenue, USD Mn, 2021 - 2033)
Teriparatide
Denosumab
Others
Global Osteogenesis Imperfecta Treatment Market, By Route of Administration:
Subcutaneous
Intravenous
Oral
Others
Global Osteogenesis Imperfecta Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
BioSenic SA
Mereo Biopharma Group PLC
CELGENE CORPORATION
Eli Lilly and Company
Cipla Inc.
Amgen Inc.
Sun Pharmaceutical Industries Ltd.
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Jubilant Pharmova Limited
Aurobindo Pharma
Quince
Ultragenyx Pharmaceutical Inc.
OrthoPediatrics Corp.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drugs
- Market Snapshot, By Route of Administration
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- New Development in Osteogenesis Imperfecta Treatment
- Pipeline Analysis
- Merger, Acquisition, Collaborations
- Funding and Investment
- Key Developments
- PEST Analysis
- PORTER's Analysis

4. Global Osteogenesis Imperfecta Treatment Market, By Drugs, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Teriparatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
Denosumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)

5. Global Osteogenesis Imperfecta Treatment Market, By Route of Administration, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segments Trends
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)

6. Global Osteogenesis Imperfecta Treatment Market, By Region, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

BioSenic SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Mereo Biopharma Group PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
CELGENE CORPORATION
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Jubilant Pharmova Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Quince
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ultragenyx Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
OrthoPediatrics Corp.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies